Key result
Delayed rapamycin reverses cardiac allograft vasculopathy, whereas delayed cyclosporine shows no effect.
Why the study?
Chronic graft vascular disease in cardiac allografts is a slowly evolving vasculopathy unresponsive to conventional immunosuppression, requiring evaluation of treatment effects.
Does delayed rapamycin treatment reverse chronic graft vascular disease in a rodent cardiac allograft model compared to cyclosporine?
Population
Rodent cardiac allograft models including PVG to ACI recipients
Comparison
Rapamycin vs cyclosporine treatment for CGVD
Design
Comparative study of 4 rodent CGVD models with immunosuppression
Follow-up
90 days
Authors
Loading...
Rodent CGVD models and Rapa/CSA effects require clinical validation; leaves open human cardiac allograft vasculopathy relevance.
Does delayed rapamycin treatment reverse chronic graft vascular disease in a rodent cardiac allograft model compared to cyclosporine?
Delayed rapamycin treatment reverses established chronic graft vascular disease in a rodent cardiac allograft model, whereas cyclosporine does not.
Poston et al. (1999) studied Chronic graft vascular disease (CGVD) in cardiac allografts (n=34). Rapamycin vs. Cyclosporine was evaluated on CGVD scores at day 90. Delayed rapamycin treatment (3 mg/kg/day) reversed chronic graft vascular disease in PVG cardiac allografts by day 90 (score 0.22±0.19), whereas delayed cyclosporine had no effect.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: